FDA Approves Nivolumab and Hyaluronidase-nvhy for Subcutaneous Injection By Ogkologos - February 7, 2025 52 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the CHECKMATE-67T study Source RELATED ARTICLESMORE FROM AUTHOR Manageable Safety Profile and Antitumour Activity of Zongertinib in Pretreated Patients with HER2-altered Tumours, Including NSCLC EMA Recommends Extension of Therapeutic Indications for Nivolumab and Ipilimumab to Unresectable or Advanced HCC ESMO Sarcoma and Rare Cancers Congress 2025, Lugano, Switzerland, 20-22 March MOST POPULAR ESMO Sarcoma & GIST Symposium 2022, 31 January – 2 February January 18, 2022 Enhertu Improves Survival for Metastatic “HER2-Low” Breast Cancer July 5, 2022 Opportunity and mentorship: Our new PhD programme aiming to open-up academia... July 22, 2022 Selpercatinib Slows Progression of RET-Positive Lung, Medullary Thyroid Cancers November 15, 2023 Load more HOT NEWS Lung Cancer Treatment Research Enters a New Era Socioeconomic Deprivation Associated with Worse Survival in Patients with Cancer Included... Rusfertide Nearly Eliminates Need for Phlebotomies to Treat Polycythemia Vera Pruebas genéticas para el cáncer en familias: Preguntas y respuestas con...
